| Document |
Document Title |
|
WO/2024/096707A1 |
The present invention relates to: a composition for preventing or treating Moyamoya disease, comprising, as an active ingredient, miRNAs or extracellular vesicles comprising same; and a composition for preventing or treating Moyamoya dis...
|
|
WO/2024/097901A1 |
. Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional...
|
|
WO/2024/097904A1 |
This disclosure provides, among other things, an engineered immunosuppressive (e.g., CD4+) T cell comprising a molecular circuit comprising the following components: (a) a central nervous system (CNS)-specific binding-triggered transcrip...
|
|
WO/2024/092339A1 |
A hybrid microgel, comprising a thermoresponsive polymer, and a polysaccharide comprising amorphous domains, the thermoresponsive polymer being grafted to the polysaccharide; methods of making the hybrid microgel, and compositions useful...
|
|
WO/2024/097315A2 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/096090A1 |
Disclosed is a microphysiological system comprising a microfluidic device, and human renal proximal tubular epithelial cells (RPTEC) and pluripotent stem cell-derived LTL-positive cells which are accommodated in the microfluidic device. ...
|
|
WO/2024/096138A1 |
This culture device comprises a container body that houses a culture liquid, and a culture chip that forms a culture chamber inside the container body, wherein: the container body has a light-permeable and gas-permeable bottom wall; and ...
|
|
WO/2024/092343A1 |
A cell culture bioreactor has hollow fiber membranes within an extra-capillary space optionally used to grow cells in suspension. The membranes may include liquid perfusion membranes and/or gas transfer membranes. Liquid medium moves wit...
|
|
WO/2024/097637A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a human BRAFV600E amino acid sequence. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression ...
|
|
WO/2024/097655A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecu...
|
|
WO/2024/097800A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/097276A1 |
This document relates to methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor (CAR) T cells having reduced levels of an interleukin (IL) 4 polypeptide, having reduced l...
|
|
WO/2024/093652A1 |
The present invention discloses a nanobody targeting IL-6Rα protein and uses thereof, wherein the heavy chain variable region of the nanobody comprises three complementary determining regions, CDR1, CDR2, and CDR3, wherein CDR1 has an a...
|
|
WO/2024/092375A1 |
The invention discloses a method for preparing a composition of mitochondria isolated from umbilical cord mesenchymal stromal cells (UC-MSC) and enriched with mitochondrial antiviral-signalling (MAVS) protein, and the use of this composi...
|
|
WO/2024/097814A1 |
The invention provides methods for upregulating mitochondrial and/or glycolytic metabolism in T cells by increasing the flux of pyruvate into the citric acid cycle, thereby increasing mitochondrial and/or glycolytic metabolism. In genera...
|
|
WO/2024/097900A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-2325 and compositions, methods, and uses thereof.
|
|
WO/2024/020484A3 |
RNA molecules comprising a guide sequence portion consisting of 17-50 nucleotides and containing 17-22 nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-20347, and compositions, methods, and uses thereof.
|
|
WO/2024/040081A3 |
The present disclosure describes methods of generating a transgenic cell or mouse that expresses a chimeric c-KIT protein capable of expression on mouse cells and binding to mouse stem cell factor (SCF) which can be inhibited by anti-hum...
|
|
WO/2024/097892A1 |
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other t...
|
|
WO/2024/093790A1 |
The present application relates to the field of biotechnology, and in particular, to a stable and high-yield targeted integration cell, a method for preparing same, and use thereof. Compared with conventional techniques, the present appl...
|
|
WO/2024/094159A1 |
Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
|
|
WO/2024/098019A1 |
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...
|
|
WO/2024/094017A1 |
Provided are a GPC3 bispecific antigen binding molecule or an antigen binding fragment thereof, a derivative containing the bispecific antigen binding molecule or the antigen binding fragment thereof, and a pharmaceutical composition. In...
|
|
WO/2024/098024A1 |
Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetic...
|
|
WO/2024/094165A1 |
A B7H3 binding polypeptide, comprising two different anti-B7H3 single domain antibodies. The present invention further relates to a chimeric antigen receptor comprising the B7H3 binding polypeptide, and a universal CAR-T cell comprising ...
|
|
WO/2024/098037A1 |
The present disclosure provides chimeric receptor constructs comprising a CD3e extracellular domain and engineered NK and T cells expressing such receptors and methods of making and using same for the treatment of cancer and other diseas...
|
|
WO/2024/097738A1 |
A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiven...
|
|
WO/2024/098036A1 |
The subject matter described here relates to anti -PAG antibodies. The subject matter described here also provides a pharmaceutical composition of, or a kit for generating an anti-PAG antibody; a method of making an anti-PAG antibody; a ...
|
|
WO/2024/096120A1 |
The present disclosure relates to improving the colonization properties of a bacterial preparation in a host. Specifically, the present disclosure relates to a microorganism wherein at least one gene is modified, said modification improv...
|
|
WO/2024/093147A1 |
The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
|
|
WO/2024/095599A1 |
Provided is a method for producing glomus cell-like cells, the method including: (a) a step for inducing differentiation of pluripotent stem cells into autonomic progenitor cells; and (b) a step for culturing the autonomic progenitor cel...
|
|
WO/2024/096506A1 |
The present invention relates to a method for preparing a high-concentration liquid medium having reduced osmotic pressure, and a method for producing a protein of interest by using the medium. When the high-concentration liquid medium i...
|
|
WO/2024/097911A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/096009A1 |
The purpose of the present invention is to provide sperm having high motility. The present invention is a sperm treatment composition that contains an exosome. A sperm treatment composition according to the present invention is used as a...
|
|
WO/2024/092300A1 |
The present disclosure relates to methods for differentiating mesenchymal stem cells (MSCs) towards an osteogenic lineage using daily short exposure to acoustic wave energy at a frequency greater than 1MHz. Methods disclosed herein can b...
|
|
WO/2024/095733A1 |
The present disclosure relates to a biological tissue model that includes two or more tissue fragments containing a bioink print and that has a structure in which the tissue fragments are adhered together, wherein the bioink contains a f...
|
|
WO/2024/094887A1 |
The present invention relates to the production of skin substitutes with a defined ratio of blood endothelial cells (BEC), to lymphatic endothelial cells (LEC), and their use in medicine.
|
|
WO/2024/095913A1 |
Provided is a means for further improving the accuracy of evaluations of pharmacokinetics, toxicity, and drug efficacy using cell aggregates from multiple samples. A plate having a plurality of wells, wherein the wells house a liquid and...
|
|
WO/2024/097763A1 |
The present application is directed to multiplex intein-based methods and compositions for the generation engineered cells expressing modular polypeptides, for example CARs and CCRs.
|
|
WO/2024/094004A1 |
The invention belongs to the technical field of cell immune engineering, and particularly relates to a fully human antigen binding fragment and single chain fragment variable targeting CD123, and a use thereof. The single chain fragment ...
|
|
WO/2024/094037A1 |
Provided is an additive composition for culture media, comprising a first component comprising at least one sample extract prepared from at least one natural substance, wherein the at least one natural substance is selected from a group ...
|
|
WO/2024/092508A1 |
Provided are a method of a mesenchymal stem cell, e.g., a placenta-derived mesenchymal stem cell, for enhancing the treatment of a tumor by a CAR-T cell and/or treating a tumor in combination with a CAR-T cell, corresponding use, and a c...
|
|
WO/2024/098027A1 |
Provided herein are TILs that are in CD39, CD103 and/or both. In some embodiments, the subject TILs are produced by genetically manipulating a population of TILs that have been selected for expression of (i) PD-1, (ii) CD39, (iii) CD103,...
|
|
WO/2024/095130A1 |
Provided herein is an engineered immunoglobulin (Ig) variable domain comprising or capable of comprising at least one non-canonical disulfide bond formed between a first cysteine and a second cysteine, wherein the first and second cystei...
|
|
WO/2024/093882A1 |
Provided are a group CD24 binding proteins and uses thereof. Specifically provided is a group of antigen binding proteins, wherein cells expressing the antigen binding protein can have cytotoxicity and safety. Also provided is a use of t...
|
|
WO/2024/097852A1 |
This document relates to methods and materials for using engineered mesenchymal stromal cells (MSCs) to treat a mammal (e.g., a human) in need of immunosuppression (e.g., a human having or at risk of developing one or more autoimmune dis...
|
|
WO/2024/092321A1 |
The present disclosure relates to methods for modifying endothelial barrier function and cellular organisation through exposure to acoustic wave energy. In vitro models of endothelial barrier function and cellular organisation and method...
|
|
WO/2024/096318A1 |
The present disclosure provides a method for isolating an exosome with increased exosome isolation efficiency, and a cosmetic composition comprising an exosome having improved wrinkle amelioration, cell proliferation, wound healing, or w...
|
|
WO/2024/095996A1 |
The purpose of the present invention is to provide an excellent infertility treatment with which it is possible to increase the implantation rate of an embryo (fertilized egg) by improving the uterine environment. The present invention i...
|
|
WO/2024/097851A1 |
Disclosed herein are method for treating an autoimmune or inflammatory disease in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising an antibody that inhibits binding of CD...
|
